504-505 / 1708
Phase II trial of selumetinib in patients with
recurrent/progressive LGG.
25 patients with NF-1 enrolled
on stratum 3, there were 10 PR,
14 SD and 1 PD while the
patients were on treatment.
No visual assessments
The 2 year PFS for stratum 3
was 96+4%.
(Personal communication
Fangusaro and Onar-Thomas,
2017).